AR091569A1 - Receptores de tipo toll - Google Patents

Receptores de tipo toll

Info

Publication number
AR091569A1
AR091569A1 ARP130102257A AR091569A1 AR 091569 A1 AR091569 A1 AR 091569A1 AR P130102257 A ARP130102257 A AR P130102257A AR 091569 A1 AR091569 A1 AR 091569A1
Authority
AR
Argentina
Prior art keywords
toll type
type receivers
immunostimulatory oligodeoxynucleotides
toll
type receptors
Prior art date
Application number
Other languages
English (en)
Original Assignee
Intervet Int Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intervet Int Bv filed Critical Intervet Int Bv
Publication of AR091569A1 publication Critical patent/AR091569A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5038—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving detection of metabolites per se
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)

Abstract

La presente solicitud se refiere a receptores de tipo ToIl, a células que comprenden dichos receptores de tipo Toll, a métodos para la detección de oligodesoxinucleótidos inmunoestimulantes, donde dichos métodos utilizan dichos receptores de tipo Toll; a oligodesoxinucleótidos inmunoestimulantes de fórmula general [tcg]ₙ donde n ³ 6 detectados por el uso de este método; al uso de dichos oligodesoxinucleótidos inmunoestimulantes en medicina, y a vacunas que comprenden dichos oligodesoxinucleótidos inmunoestimulantes.
ARP130102257 2012-06-28 2013-06-26 Receptores de tipo toll AR091569A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12174199 2012-06-28

Publications (1)

Publication Number Publication Date
AR091569A1 true AR091569A1 (es) 2015-02-11

Family

ID=48699818

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130102257 AR091569A1 (es) 2012-06-28 2013-06-26 Receptores de tipo toll

Country Status (14)

Country Link
US (1) US10112985B2 (es)
EP (1) EP2867249B1 (es)
JP (1) JP6427487B2 (es)
KR (1) KR20150023465A (es)
CN (1) CN104718221B (es)
AR (1) AR091569A1 (es)
AU (1) AU2013283359A1 (es)
CA (1) CA2873288A1 (es)
ES (1) ES2673899T3 (es)
MX (1) MX2014015766A (es)
NZ (1) NZ701803A (es)
RU (1) RU2015102611A (es)
WO (1) WO2014001422A2 (es)
ZA (1) ZA201408773B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2017017141A (es) * 2015-06-26 2018-03-09 Bayer Animal Health Gmbh Metodos de modulacion de moleculas de vigilancia de adn citosolicas.
WO2017214378A1 (en) 2016-06-08 2017-12-14 President And Fellows Of Harvard College Engineered viral vector reduces induction of inflammatory and immune responses
BR112020011838A2 (pt) * 2017-12-15 2020-11-24 Bayer Animal Health Gmbh oligonucleotídeos imunoestimulatórios
US20210364497A1 (en) * 2018-04-02 2021-11-25 University Of Miami IFN-beta Reporter System for Primary Cells

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7696338B2 (en) * 1995-10-30 2010-04-13 The United States Of America As Represented By The Department Of Health And Human Services Immunotoxin fusion proteins and means for expression thereof
US5948677A (en) 1996-12-09 1999-09-07 Jarvik; Jonathan W. Reading frame independent epitope tagging
AU4175101A (en) 2000-02-23 2001-09-03 Univ California Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation
US20040131628A1 (en) * 2000-03-08 2004-07-08 Bratzler Robert L. Nucleic acids for the treatment of disorders associated with microorganisms
CN1271733A (zh) 2000-04-04 2000-11-01 中国预防医学科学院病毒学研究所 对人免疫细胞有特异免疫刺激活性的CpG寡核酸
SE0201701D0 (sv) * 2002-06-05 2002-06-05 Gotovax Ab Treatment of epithelial tumors and infections
AR040996A1 (es) 2002-08-19 2005-04-27 Coley Pharm Group Inc Acidos nucleicos inmunoestimuladores
WO2004026888A2 (en) * 2002-09-19 2004-04-01 Coley Pharmaceutical Gmbh Toll-like receptor 9 (tlr9) from various mammalian species
WO2005001116A1 (ja) * 2003-06-17 2005-01-06 Meiji Dairies Corporation Toll様レセプター強制発現細胞の利用
JP3976742B2 (ja) * 2004-02-27 2007-09-19 江守商事株式会社 インターフェロンアルファを誘導する免疫刺激オリゴヌクレオチド
US7647679B2 (en) 2007-07-03 2010-01-19 Hardinge, Inc. Belt-driven indexing tool turret assembly
FR2954703B1 (fr) * 2009-12-28 2013-12-13 Chu Nantes Agonistes des recepteurs tlr 4 et 9 pour prevenir les complications septiques de l'immunodepression post-traumatique chez les patients hospitalises pour traumatismes severes
EP2471926A3 (en) 2010-12-30 2012-07-11 Intervet International BV Immunostimulatory oligodeoxynucleotides
EP2714907B1 (en) 2011-05-26 2016-06-15 Intervet International B.V. Immunostimulatory oligodeoxynucleotides
US9315814B2 (en) * 2011-05-26 2016-04-19 Intervet Inc. Immunostimulatory oligodeoxynucleotides

Also Published As

Publication number Publication date
CA2873288A1 (en) 2014-01-03
US10112985B2 (en) 2018-10-30
JP2015522266A (ja) 2015-08-06
MX2014015766A (es) 2015-04-10
ES2673899T3 (es) 2018-06-26
CN104718221B (zh) 2018-06-26
JP6427487B2 (ja) 2018-11-21
EP2867249A2 (en) 2015-05-06
WO2014001422A3 (en) 2014-02-27
EP2867249B1 (en) 2018-04-18
AU2013283359A1 (en) 2014-11-27
CN104718221A (zh) 2015-06-17
RU2015102611A (ru) 2016-08-20
NZ701803A (en) 2017-06-30
WO2014001422A2 (en) 2014-01-03
US20150191523A1 (en) 2015-07-09
ZA201408773B (en) 2015-12-23
KR20150023465A (ko) 2015-03-05

Similar Documents

Publication Publication Date Title
NI201400125A (es) Antagonistas de st2l y métodos de uso
DOP2014000203A (es) Compuestos de heterociclilo
BR112014007852A2 (pt) nucleosídeos, nucleotídeos e ácidos nucleicos modificados e usos dos mesmos
EA201291157A1 (ru) Мультивалентные вакцины с синтетическими наноносителями
BR112013023681A2 (pt) compostos de álcool propargílico 6,5-heterocíclico e uso dos mesmos
BR112013031493A2 (pt) composto, composição farmacêutica, uso de um composto, combinação de um composto, dispositivo e processo de preparação de um composto.
UY34350A (es) Derivados de pirazolquinolinona, su preparación y su uso terapéutico.
BR112013020070A2 (pt) moléculas de ácido nucleico que codificam novos antígenos de herpes, vacina compreendendo as mesmas e métodos de uso das mesmas
CR20130543A (es) Derivados de pirrolotriazinona como inhibidores de pi3k
ECSP12012221A (es) Anticuerpos anti-cd40
BR112012018345A2 (pt) "compostos de heteroarila, bem como composições e usos dos mesmos"
BR112014010433A2 (pt) método e máquina para produzir uma cápsula de uso único para bebidas e cápsula obtida com o método
NI201500054A (es) Derivados de pirrolotriazinona como inhibidores de pi3k
DOP2013000307A (es) Antagonistas de trpv4
MX346596B (es) Oligodesoxinucleotidos inmunoestimuladores.
CO6920294A2 (es) Derivados de estra-1,3,5(10),16-tetraen-3-carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos
UY34406A (es) Compuestos y métodos para mejorar la respuesta inmune innata
BR112012030742A2 (pt) ésteres de dialcanolamina quaternários
CL2013002823A1 (es) Compuestos derivados de morfolinotieno[3,2-d]pirimidin-6-il-metil-(metilamino)-n-hidroxipirimidina-5-carboxamida, inhibidores de la pi3 quinasa; composicion farmaceutica que los comprende; su uso en el tratamiento de un trastorno de proliferacion celular tal como el cancer.
BR112013015083A2 (pt) sistema para uso com um poço
BR112012031861A2 (pt) uso de 5a-androstano (alquil)-3b, 5, 6b-triol
BR112015008824A2 (pt) linhagens melhoradas de microalgas e processo das mesmas
CL2013003093A1 (es) Composiciones que comprende cation de polihidroxioxoaluminio detectable por rmn; metodo de fabricacion de los mismos; y su uso.
BR112012030412A2 (pt) ésteres de dialcanolamina quaternários
AR091569A1 (es) Receptores de tipo toll

Legal Events

Date Code Title Description
FB Suspension of granting procedure